Compare MVST & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MVST | ACOG |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.0M | 193.6M |
| IPO Year | 2019 | 2024 |
| Metric | MVST | ACOG |
|---|---|---|
| Price | $0.61 | $9.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 2.8M | 98.5K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.25 | 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $427,516,000.00 | $10,220,275.00 |
| Revenue This Year | N/A | $153.46 |
| Revenue Next Year | $29.58 | $85.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.56 | N/A |
| 52 Week Low | $0.47 | $4.50 |
| 52 Week High | $5.85 | $10.14 |
| Indicator | MVST | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 58.86 |
| Support Level | $0.56 | $5.49 |
| Resistance Level | $0.75 | $9.48 |
| Average True Range (ATR) | 0.04 | 0.46 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 95.26 | 97.51 |
Microvast Holdings Inc develops lithium-ion battery technologies focused on high-performance solutions for commercial and industrial electrification. The Company designs, develops, and manufactures battery components and systems for electric commercial vehicles and energy storage systems (ESS), with applications across buses, trucks, port equipment, and mining machinery. It emphasizes innovation in battery design without relying on legacy technologies and supports platforms such as the IVECO eDaily and various bus models. The Company also provides services, repairs, and warranty and extended warranty support. It operates as a single reportable segment, covering design, development, manufacturing, sales, and leasing of battery systems, and generates the majority of its revenue from Europe.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.